Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases — Stella

Home/Relapsed/Refractory Systemic Lupus Erythematosus/

View on ClinicalTrials.gov

Recruiting

Back to Relapsed/Refractory Systemic Lupus Erythematosus trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Beijing GoBroad Boren Hospital, Beijing

Key details

Phase

Early testing

Sponsor

Beijing Boren Hospital

Enrollment target

~12 participants

Started

November 2025

Primary completion

June 2028

Age range

18 Years – 70 Years

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.